Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Mayer

Showing results (131-140 of 133) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 133 results.
Plos Biology|March 12, 2024
Synaptic and dendritic architecture of different types of hippocampal somatostatin interneuronsVirág Takács, Zsuzsanna Bardóczi, Áron Orosz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2020
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancerH S Rugo, F André, T Yamashita, et al.
ESMO Open|March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancerS Jacob, E L Mayer, N Kacik, et al.
Pageof 14

Showing results (131-140 of 133) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 133 results.
Plos Biology|March 12, 2024
Synaptic and dendritic architecture of different types of hippocampal somatostatin interneuronsVirág Takács, Zsuzsanna Bardóczi, Áron Orosz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2020
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancerH S Rugo, F André, T Yamashita, et al.
ESMO Open|March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancerS Jacob, E L Mayer, N Kacik, et al.
Pageof 14